A development stage pharmaceutical company that seeks to acquire and develop innovative products for the treatment of a variety of human diseases.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
CAPS gypped me out of my sub-4 Chelsea pick last month so I closed it for a positive score, knowing market volatility would give me another opportunity. I expect Chelsea to submit the NDA for Northera for neurogenic orthostatic hypotension in the near future. The company has stated they anticipate a six month priority review, which would indicate a PDUFA in March or April of 2012. Meanwhile, interim efficacy data from the phase II trial of CH-4051 is also expected very shortly, and I expect this to be positive based on phase II data from predecessor anti-folate CH-1504 from March 2009. Northera is also in trials for other diverse indications such as Parkinsonian orthostatic hypotension and ADHD.